Showing results (141-150 of 160) with videos related to
Sort By:
Pageof 16
European Journal of Nuclear Medicine and Molecular Imaging|January 15, 2019
Interim analysis of the REASSURE (Radium-223 alpha Emitter Agent in non-intervention Safety Study in mCRPC popUlation for long-teRm Evaluation) study: patient characteristics and safety according to prior use of chemotherapy in routine clinical practiceSabina Dizdarevic, Peter Meidahl Petersen, Markus Essler, et al.Clinical Nuclear Medicine|January 9, 2025
225 Ac-PSMA-617 Augmentation After Insufficient Response Under 177 Lu-PSMA-617 Radioligand Therapy in mCRPC: Evaluation of Outcome and Safety From a Prospective Registry (REALITY Study)Florian Rosar, Fadi Khreish, Lea Sophie Nagel, et al.Molecular Pharmaceutics|November 18, 2023
Radiometal Complexes as Pharmacokinetic Modifiers: A Potent 68Ga-Labeled Gastrin-Releasing Peptide Receptor Antagonist Based on the Macrocyclic Metal Chelator NODIA-MeMoritz-Valentin Schreck, Caroline Burgard, Alexander Schmidtke, et al.European Journal of Nuclear Medicine and Molecular Imaging|July 7, 2026
Real-world evaluation of [177Lu]Lu-PSMA-617 RLT in post-taxane mCRPC: feasibility and safety of individualized treatment in a challenging cohortMuammer Misirci, Florian Rosar, Fadi Khreish, et al.European Journal of Nuclear Medicine and Molecular Imaging|August 5, 2022
[89Zr]Zr-PSMA-617 PET/CT in biochemical recurrence of prostate cancer: first clinical experience from a pilot study including biodistribution and dose estimatesFlorian Rosar, Andrea Schaefer-Schuler, Mark Bartholomä, et al.Applied Radiation and Isotopes : Including Data, Instrumentation and Methods for Use in Agriculture, Industry and Medicine|January 30, 2021
Impact of prompt gamma emission of 44Sc on quantification in preclinical and clinical PET systemsFlorian Rosar, Hendrik Bohnenberger, Euy Sung Moon, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 30, 2003
Repeated bone-targeted therapy for hormone-refractory prostate carcinoma: tandomized phase II trial with the new, high-energy radiopharmaceutical rhenium-188 hydroxyethylidenediphosphonateHolger Palmedo, Agnieska Manka-Waluch, Peter Albers, et al.European Journal of Cancer (Oxford, England : 1990)|March 5, 2016
Effectiveness and side-effects of peptide receptor radionuclide therapy for neuroendocrine neoplasms in Germany: A multi-institutional registry study with prospective follow-upDieter Hörsch, Samer Ezziddin, Alexander Haug, et al.Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|June 25, 2021
177Lu-Prostate-Specific Membrane Antigen Ligand After 223Ra Treatment in Men with Bone-Metastatic Castration-Resistant Prostate Cancer: Real-World Clinical ExperienceOliver Sartor, Christian la Fougère, Markus Essler, et al.Recent Results in Cancer Research. Fortschritte Der Krebsforschung. Progres Dans Les Recherches Sur Le Cancer|August 25, 2012
Peptide receptor radionuclide therapy for neuroendocrine tumors in Germany: first results of a multi-institutional cancer registryDieter Hörsch, Samer Ezziddin, Alexander Haug, et al.Pageof 16